These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


229 related items for PubMed ID: 33923732

  • 1. Expression of Estrogen Receptor- and Progesterone Receptor-Regulating MicroRNAs in Breast Cancer.
    Kalinina T, Kononchuk V, Alekseenok E, Obukhova D, Sidorov S, Strunkin D, Gulyaeva L.
    Genes (Basel); 2021 Apr 16; 12(4):. PubMed ID: 33923732
    [Abstract] [Full Text] [Related]

  • 2. MicroRNA regulation of progesterone receptor in breast cancer.
    Gilam A, Shai A, Ashkenazi I, Sarid LA, Drobot A, Bickel A, Shomron N.
    Oncotarget; 2017 Apr 18; 8(16):25963-25976. PubMed ID: 28404930
    [Abstract] [Full Text] [Related]

  • 3. Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen.
    McFall T, McKnight B, Rosati R, Kim S, Huang Y, Viola-Villegas N, Ratnam M.
    J Biol Chem; 2018 Jan 26; 293(4):1163-1177. PubMed ID: 29162724
    [Abstract] [Full Text] [Related]

  • 4. Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer.
    McDermott AM, Miller N, Wall D, Martyn LM, Ball G, Sweeney KJ, Kerin MJ.
    PLoS One; 2014 Jan 26; 9(1):e87032. PubMed ID: 24498016
    [Abstract] [Full Text] [Related]

  • 5. Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status.
    Payandeh M, Shahriari-Ahmadi A, Sadeghi M, Sadeghi E.
    Asian Pac J Cancer Prev; 2016 Jan 26; 17(3):1015-8. PubMed ID: 27039719
    [Abstract] [Full Text] [Related]

  • 6. Down-regulation of microRNA-19b in hormone receptor-positive/HER2-negative breast cancer.
    Maleki E, Ghaedi K, Shahanipoor K, Karimi Kurdistani Z.
    APMIS; 2018 Apr 26; 126(4):303-308. PubMed ID: 29575198
    [Abstract] [Full Text] [Related]

  • 7. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
    Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ.
    Breast Cancer Res; 2009 Apr 26; 11(3):R27. PubMed ID: 19432961
    [Abstract] [Full Text] [Related]

  • 8. miRNA as potential biomarkers of breast cancer in the Lebanese population and in young women: a pilot study.
    Nassar FJ, El Sabban M, Zgheib NK, Tfayli A, Boulos F, Jabbour M, El Saghir NS, Talhouk R, Bazarbachi A, Calin GA, Nasr R.
    PLoS One; 2014 Apr 26; 9(9):e107566. PubMed ID: 25232827
    [Abstract] [Full Text] [Related]

  • 9. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
    Gong C, Tan W, Chen K, You N, Zhu S, Liang G, Xie X, Li Q, Zeng Y, Ouyang N, Li Z, Zeng M, Zhuang S, Lau WY, Liu Q, Yin D, Wang X, Su F, Song E.
    EBioMedicine; 2016 Sep 26; 11():199-209. PubMed ID: 27566954
    [Abstract] [Full Text] [Related]

  • 10. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study.
    Moi L, Braaten T, Al-Shibli K, Lund E, Busund LR.
    J Transl Med; 2019 Oct 03; 17(1):334. PubMed ID: 31581940
    [Abstract] [Full Text] [Related]

  • 11. TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC.
    Petrovic N, Sami A, Martinovic J, Zaric M, Nakashidze I, Lukic S, Jovanovic-Cupic S.
    Pathol Res Pract; 2017 Oct 03; 213(10):1264-1270. PubMed ID: 28935174
    [Abstract] [Full Text] [Related]

  • 12. Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis.
    Tas F.
    Onkologie; 2012 Oct 03; 35(3):95-8. PubMed ID: 22414972
    [Abstract] [Full Text] [Related]

  • 13. Correlation of miRNA expression profiling in surgical pathology materials, with Ki-67, HER2, ER and PR in breast cancer patients.
    Sakurai M, Masuda M, Miki Y, Hirakawa H, Suzuki T, Sasano H.
    Int J Biol Markers; 2015 May 26; 30(2):e190-9. PubMed ID: 25907662
    [Abstract] [Full Text] [Related]

  • 14. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.
    Shen Q, Sahin AA, Hess KR, Suki D, Aldape KD, Sawaya R, Ibrahim NK.
    Oncologist; 2015 May 26; 20(5):466-73. PubMed ID: 25802405
    [Abstract] [Full Text] [Related]

  • 15. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
    Sechrist H, Glasgow A, Bomeisl P, Gilmore H, Harbhajanka A.
    Hum Pathol; 2020 Oct 26; 104():54-65. PubMed ID: 32758491
    [Abstract] [Full Text] [Related]

  • 16. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
    Sujarittanakarn S, Himakhun W, Worasawate W, Prasert W.
    Asian Pac J Cancer Prev; 2020 Jun 01; 21(6):1559-1565. PubMed ID: 32592349
    [Abstract] [Full Text] [Related]

  • 17. Clinical Value of miR-101-3p and Biological Analysis of its Prospective Targets in Breast Cancer: A Study Based on The Cancer Genome Atlas (TCGA) and Bioinformatics.
    Li CY, Xiong DD, Huang CQ, He RQ, Liang HW, Pan DH, Wang HL, Wang YW, Zhu HW, Chen G.
    Med Sci Monit; 2017 Apr 18; 23():1857-1871. PubMed ID: 28416776
    [Abstract] [Full Text] [Related]

  • 18. Expression analysis of MiR-21, MiR-205, and MiR-342 in breast cancer in Iran.
    Savad S, Mehdipour P, Miryounesi M, Shirkoohi R, Fereidooni F, Mansouri F, Modarressi MH.
    Asian Pac J Cancer Prev; 2012 Apr 18; 13(3):873-7. PubMed ID: 22631664
    [Abstract] [Full Text] [Related]

  • 19. MicroRNAs and metastasis-related gene expression in Egyptian breast cancer patients.
    Hafez MM, Hassan ZK, Zekri AR, Gaber AA, Al Rejaie SS, Sayed-Ahmed MM, Al Shabanah O.
    Asian Pac J Cancer Prev; 2012 Apr 18; 13(2):591-8. PubMed ID: 22524830
    [Abstract] [Full Text] [Related]

  • 20. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY, Kim S, Lee JH, Lee HC, Lee SK, Kil WH, Kim SW, Lee JE, Nam SJ.
    BMC Cancer; 2015 Mar 18; 15():138. PubMed ID: 25880075
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 12.